Vemurafenib

Generic Name
Vemurafenib
Brand Names
Zelboraf
Drug Type
Small Molecule
Chemical Formula
C23H18ClF2N3O3S
CAS Number
918504-65-1
Unique Ingredient Identifier
207SMY3FQT
Background

Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collab...

Indication

Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E. The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.
...

Associated Conditions
Metastatic Melanoma, Refractory Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Erdheim-Chester disease
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath